Hangzhou Highlightll Pharmaceutical Co., Ltd. 杭州高光製藥股份有限公司 (A joint stock company established in the People's Republic of China with limited liability) WARNING The publication of this Application Proof is required by The Stock Exchange of Hong Kong Limited (the "Stock Exchange") and the Securities and Futures Commission (the "Commission") solely for the purpose of providing information to the public in Hong Kong. This Application Proof is in draft form. The information contained in it is incomplete and is s ...

Upgrades - Argus upgraded Herbalife (HLF) to Buy from Hold, citing a Q3 earnings beat and raising FY25 EPS view by $0.03 to $2.15 and FY26 view by $0.04 to $2.64 [2] - JPMorgan upgraded Atmus Filtration (ATMU) to Overweight from Neutral with a price target increase to $60 from $53, following the proposed acquisition of Koch Filter [2] - Morgan Stanley upgraded Amentum (AMTM) to Equal Weight from Underweight, raising the price target to $35 from $20, indicating a more balanced risk/reward at current share levels [3] - Northland upgraded NetApp (NTAP) to Outperform from Market Perform, increasing the price target to $137 from $120, after reporting revenue growth of 4% year-over-year in fiscal Q2 and guidance for 5% growth in the second half of FY26 [3] - Deutsche Bank upgraded Autodesk (ADSK) to Buy from Hold, raising the price target to $375 from $345, following "very healthy" Q3 results described as one of the "cleanest" quarterly prints in recent years [4] Downgrades - Macquarie downgraded Nio (NIO) to Neutral from Outperform, lowering the price target to $5.30 from $6.70, after issuing "weak" Q4 volume guidance of 122,500 units at the midpoint [5] - Craig-Hallum downgraded PagerDuty (PD) to Hold from Buy, reducing the price target to $15 from $20, noting a fundamental change in end markets negatively affecting PagerDuty [5] - UBS downgraded Biohaven (BHVN) to Neutral from Buy, with a price target decrease to $11 from $26, citing multiple R&D and regulatory setbacks impacting confidence in its pipeline [5] - Bernstein downgraded Ambev (ABEV) to Market Perform from Outperform, setting a price target of $2.88, attributing the downgrade to valuation concerns as shares rose 16% year-to-date [5] - RBC Capital downgraded Morgan Stanley Direct Lending (MSDL) to Sector Perform from Outperform, lowering the price target to $18 from $19, suggesting lower net interest income return on equity expectations for 2026 [5]

Core Insights - Biohaven Ltd. (NYSE:BHVN) is perceived as undervalued, with potential for growth in the market despite concerns about bias due to personal dealings with the company [1][2]. Company Overview - Biohaven Ltd. focuses on developing treatments for neurological, psychiatric, autoimmune, and cancer-related conditions, with multiple drugs currently in clinical trials [2]. Analyst Commentary - Jim Cramer highlighted that Biohaven's stock price appears low, expressing surprise at its current valuation following an analyst day that did not generate excitement [2]. - Cramer acknowledged his personal deal with Biohaven, which may influence his perspective, but maintains that the stock represents a buying opportunity [2]. Market Comparison - While Biohaven is recognized for its potential, there is a belief that certain AI stocks may offer greater upside potential and lower downside risk compared to Biohaven [2].

Core Insights - Biohaven's executives, including the CEO and key directors, have collectively purchased over $33 million worth of their own stock, signaling strong confidence in the company's undervalued position [3] - The stock has experienced a significant decline of over 74% year-to-date, primarily due to a regulatory setback from the FDA regarding its drug candidate, troriluzole [4] - Following the stock's drop to a 52-week low of $7.48, Biohaven's management has implemented a strategic reprioritization, focusing on three promising late-stage clinical programs and reducing annual R&D spending by an estimated 60% [5] Company Strategy - The substantial share purchases by top executives indicate a strong alignment of their financial interests with those of shareholders, reinforcing confidence in the company's future [6] - The management's strategic pivot aims to concentrate resources on high-potential clinical assets, enhancing future growth and value creation [6] - Biohaven's streamlined pipeline includes multiple high-potential drug candidates, with significant data readouts expected in the upcoming quarters [6]

Company Overview - Biohaven Ltd. is a clinical-stage biopharmaceutical company focused on developing therapies for neurological and immunoscience conditions, aiming to address significant gaps in current treatment paradigms [1] - The company operates with a strategy centered on scientific innovation and targets unmet medical needs in healthcare [1][5] Insider Activity - Chief Accounting Officer George Clark purchased 17,000 shares of Biohaven on November 17, 2025, marking his first open-market purchase in two years [4] - Following this transaction, Mr. Clark's total ownership increased to 85,595 shares, representing approximately 0.062% of Biohaven's outstanding shares [2][3] Stock Performance - The shares were acquired at a weighted average price of $8.52, while the market closed at $8.27 on the transaction date and was at $9.45 as of November 18, 2025 [3] - The stock recently hit a 52-week low of $7.48 on November 11, 2025, a significant drop from its high of $47.75 nearly a year ago [6] Financial Performance - Biohaven reported a net loss of $173.4 million in Q3, an increase from $160.3 million in the prior year, and ended the quarter with approximately $264 million in cash and investments [8] - To strengthen its balance sheet, the company implemented an equity offering that generated about $200 million [8] Regulatory Challenges - The U.S. FDA rejected Biohaven's request for approval of its lead drug, troriluzole, on November 4, 2025, prompting the company to announce cost-cutting measures shortly thereafter [7] - As an early-stage biotechnology company, Biohaven does not currently generate revenue and relies on regulatory approval to begin selling its drugs [7]

Core Insights - Biohaven Ltd. is recognized as a promising small-cap biotech stock by analysts [1] - William Blair maintains a "Market Perform" rating, highlighting the FDA's Complete Response Letter for Vyglxia as a pivotal factor for pipeline reprioritization [2] - The company reported a net loss of $173.4 million in Q3 2025, an increase from the previous year's loss, but showed improvement in non-GAAP net loss due to cost management [3][4] Financial Performance - In Q3 2025, Biohaven reported a net loss of $173.4 million, or $1.64 per share, compared to a net loss of $160.3 million in Q3 2024 [3] - Non-GAAP net loss improved to $155.9 million, or $1.47 per share, attributed to reduced spending on non-priority programs [3] - The company ended the quarter with cash balances of $263.8 million despite high expenses [4] Expense Management - R&D expenses decreased from $157.6 million in Q3 2024 to $141.2 million in Q3 2025, reflecting a strategic shift in focus [4] - General and administrative expenses rose to $28.2 million, influenced by increased share-based compensation and legal costs [4] Strategic Focus - Biohaven is concentrating on therapies in immunology, neuroscience, and oncology, with a particular emphasis on late-stage programs as growth catalysts [2][5]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - Shoulder Innovations, Inc. (SI) is up 14% at $13.01 [3] - BILL Holdings, Inc. (BILL) is up 11% at $52.14 [3] - On Holding AG (ONON) is up 8% at $38.24 [3] - CuriosityStream Inc. (CURI) is up 8% at $4.08 [3] - Clearwater Analytics Holdings, Inc. (CWAN) is up 7% at $19.80 [3] - Valhi, Inc. (VHI) is up 7% at $14.54 [3] - Beam Global (BEEM) is up 7% at $2.29 [3] - FGI Industries Ltd. (FGI) is up 6% at $5.66 [3] - The Honest Company, Inc. (HNST) is up 6% at $2.68 [3] - China Automotive Systems, Inc. (CAAS) is up 5% at $4.40 [3] Premarket Losers - Graphjet Technology (GTI) is down 22% at $3.02 [4] - Black Rock Coffee Bar, Inc. (BRCB) is down 10% at $21.90 [4] - Rain Enhancement Technologies Holdco, Inc. (RAIN) is down 9% at $4.90 [4] - Stereotaxis, Inc. (STXS) is down 9% at $2.59 [4] - Biohaven Ltd. (BHVN) is down 8% at $7.82 [4] - Epsium Enterprise Limited (EPSM) is down 7% at $3.15 [4] - Cycurion, Inc. (CYCU) is down 7% at $3.13 [4] - Galecto, Inc. (GLTO) is down 6% at $22.09 [4] - Anbio Biotechnology (NNNN) is down 6% at $21.68 [4] - Ridgetech, Inc. (RDGT) is down 5% at $3.46 [4]

Group 1: LightPath Technologies Inc - LightPath Technologies Inc (NASDAQ:LPTH) reported better-than-expected first-quarter financial results, leading to a sharp rise in its shares during pre-market trading [1] - The company reported a quarterly loss of 7 cents per share, which was better than the analyst estimate of a 9-cent loss [1] - Quarterly revenue for LightPath Technologies was $15.05 million, surpassing the consensus estimate of $12.66 million [1] - Following the financial results, shares of LightPath Technologies jumped 6.8% to $8.58 in pre-market trading [1] Group 2: Other Stocks in Pre-Market Trading - Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) surged 170% to $2.65 after releasing pricing details for its underwritten public offering [6] - Kandal M Venture Limited (NASDAQ:FMFC) gained 70.4% to $0.9490 after previously falling 8% [6] - Amaze Holdings, Inc. (NYSE:AMZE) rose 68.4% to $0.8934 after extending its partnership with Adobe Express [6] - VCI Global Limited (NASDAQ:VCIG) surged 44.4% to $1.88 after a 27% dip on Tuesday [6] - Clearmind Medicine Inc. (NASDAQ:CMND) gained 27% to $0.5830 after a 32% decline on Tuesday [6] - Lucyd, Inc (NASDAQ:LUCY) surged 23.3% to $1.90 [6] - BILL Holdings, Inc (NYSE:BILL) gained 14.8% to $53.49 [6] - Cuprina Holdings (Cayman) Limited (NASDAQ:CUPR) gained 11.7% to $0.8160 after a 5% decline [6] - DBV Technologies SA – ADR (NASDAQ:DBVT) rose 8.7% to $14.50, confirming completion of Phase 3 treatment phase for VIASKIN peanut patch [6] Group 3: Decliners in Pre-Market Trading - MSP Recovery Inc (NASDAQ:MSPR) tumbled 18.2% to $0.46 after a 75% jump on Tuesday [6] - Aspire Biopharma Holdings Inc (NASDAQ:ASBP) declined 16.5% to $0.097 after a 25% dip [6] - Rain Enhancement Technologies Holdco Inc (NASDAQ:RAIN) fell 14.3% to $4.66 after a 10% gain [6] - IRIDEX Corp (NASDAQ:IRIX) shares dipped 13.4% to $1.03 following the announcement of quarterly results [6] - Leifras Co Ltd (NASDAQ:LFS) fell 13.4% to $9.82 after a significant 577% jump on Tuesday [6] - Graphjet Technology (NASDAQ:GTI) fell 12.3% to $3.40 after an 8% decline [6] - ICZOOM Group Inc (NASDAQ:IZM) fell 10.1% to $1.25 after a 34% gain [6] - Biohaven Ltd (NYSE:BHVN) dipped 7.7% to $7.86 after announcing a $150 million offering [6] - Stitch Fix Inc (NASDAQ:SFIX) dipped 4% to $4.21 [6] - Daqo New Energy Corp (NYSE:DQ) fell 3.7% to $34.29 [6]

Summary of NewAmsterdam Pharma Conference Call Company Overview - **Company**: NewAmsterdam Pharma (NasdaqGM:NAMS) - **Event**: FY Conference on November 11, 2025 Key Industry Insights - **Lipid Management**: The conference highlighted significant advancements in lipid management, particularly in the context of cardiovascular disease prevention. The recent American Heart Association (AHA) meeting emphasized the importance of LDL lowering and its correlation with mortality benefits, which is expected to shift treatment guidelines towards more aggressive LDL targets [6][54]. Core Points Discussed 1. **Mortality Benefit Evidence**: New studies have shown that aggressive LDL lowering can lead to mortality benefits, particularly in broader high-risk populations, which opens up new market opportunities for NewAmsterdam's products [6][54]. 2. **Prevail Study Design**: The Prevail study is designed to track event rates similar to previous successful studies, with a focus on achieving a significant reduction in cardiovascular events. The company is confident in the study's design and its potential outcomes [20][21][12]. 3. **Market Competition**: The competitive landscape includes Merck's oral PCSK9 inhibitor, which has shown promising LDL lowering results. However, NewAmsterdam believes its product, Obsettra, offers unique benefits, including Lp(a) lowering and potential Alzheimer's disease benefits, which could differentiate it in the market [13][15][47]. 4. **Regulatory Strategy**: NewAmsterdam plans to align its NDA submission with the completion of the Prevail study to ensure that the most relevant data is available at launch. The timing of the NDA submission is contingent on event tracking and FDA feedback [41][42][43]. 5. **Future Studies**: Additional studies, including Rubin and Rembrandt, are planned to further explore the drug's benefits in specific populations, particularly those with high Lp(a) levels and diabetes [44][45]. Additional Important Insights - **Market Growth Potential**: Analysts predict a significant market growth for lipid-lowering therapies, estimating a market size of $4 billion to $5 billion for both Merck and AstraZeneca, which NewAmsterdam aims to capture with its innovative approach [15][16]. - **Patient Compliance Concerns**: The discussion highlighted the challenges of patient compliance in real-world settings compared to clinical trials, which may affect the uptake of new therapies [13][14]. - **Emerging Technologies**: The future of lipid management is expected to be transformed by new technologies and therapies, including gene editing approaches, which could significantly impact cardiovascular disease prevention [54]. Conclusion NewAmsterdam Pharma is positioned to capitalize on the evolving landscape of lipid management with its upcoming product, Obsettra. The company is focused on leveraging new evidence supporting aggressive LDL lowering, maintaining a strategic approach to regulatory submissions, and preparing for a competitive market environment. The insights from the AHA meeting and ongoing studies will play a crucial role in shaping the company's future trajectory in the healthcare sector.

Core Viewpoint - Biohaven's stock plummeted by 40.22% to a 52-week low following the FDA's complete response letter (CRL) rejecting the approval of its main asset, Vyglxia (troriluzole) [1] Group 1: FDA Response and Market Reaction - The FDA issued a CRL for Biohaven's new drug application (NDA) for Vyglxia, which targets spinocerebellar ataxia, a rare neurodegenerative disease [1] - The stock downgrade by Bank of America from "Buy" to "Neutral" and the target price reduction from $49 to $10 reflects the negative market sentiment following the FDA's decision [1] - Biohaven's CEO expressed disappointment over the FDA's decision, indicating the company's commitment to continue discussions with the FDA regarding the drug's regulatory pathway [1] Group 2: Company Restructuring and Financial Implications - Biohaven announced a restructuring plan that includes pausing or delaying non-priority R&D projects, aiming for a 60% reduction in annual R&D spending [2] - Analyst Jason Gerberry expressed caution regarding the restructuring plan, suggesting it may limit resource allocation to the company's three core assets, including Kv7 ion channel activator Opakalim [2] - The valuation model has been adjusted to exclude projections related to troriluzole due to the uncertainty surrounding its approval [2]